Cargando…
FDA Coronavirus Treatment Acceleration Program: approved drugs and those in clinical trials
Coronavirus disease is a highly infectious disease caused by the 2019 novel coronavirus, now recognized as severe acute respiratory syndrome coronavirus 2. This pandemic caused great stress in the general public and led to the collapse of healthcare system in some places. Till date, there has not be...
Autores principales: | Nainwal, Lalit Mohan, Suman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217692/ http://dx.doi.org/10.1016/B978-0-323-85156-5.00013-4 |
Ejemplares similares
-
Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
por: De Vita, Simona, et al.
Publicado: (2020) -
FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015) -
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
por: Beakes-Read, Ginny, et al.
Publicado: (2022) -
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
por: Nishikawa, Shigeto, et al.
Publicado: (2023) -
Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)